Variational AI Raises $5.5 Million to Launch Foundation Model for Drug Discovery Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, has successfully closed…
DocGo Expands into Chattanooga Region in Collaboration with Major Tennessee Healthcare System DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced…
Reverb Therapeutics Secures $12M to Advance Amplify•R™ Platform Reverb Therapeutics, a leader in harnessing the natural immune system and cytokine signaling to treat life-threatening diseases, announced it has closed a…
Oneview Healthcare Launches ‘Ovie’ Care Assistant to Ease Nursing Burden Oneview Healthcare has launched Ovie, a groundbreaking GenAI product designed to offer personalized, real-time support for patients and their families…
GeneDx Reports Q4 and 2024 Financial Results, Provides 2025 Guidance GeneDx Holdings Corp. (Nasdaq: WGS), a leader in genomic testing for improved health outcomes, reported its financial results for the…
Cellistic Unveils Allo Chassis™: Immune-Cloaked iPSC Cell Lines for Cost-Effective Cell Therapy Cellistic, a leader in iPSC-based off-the-shelf cell therapy development and manufacturing services, has introduced its innovative Allo Chassis™—a…
FDA Approves GSK’s PENMENVY 5-in-1 Meningococcal Vaccine GSK plc (LSE/NYSE: GSK) has announced that the U.S. Food and Drug Administration (FDA) has approved its PENMENVY vaccine (Meningococcal Groups A, B,…
MED-EL USA Gets FDA Approval for SONNET 3 Audio Processor MED-EL USA has announced the U.S. Food and Drug Administration (FDA) approval of its latest innovation, the SONNET 3 audio…
UroGen Shares ENVISION Trial Subgroup Analysis on Tumor Burden and UGN-102 Response UroGen Pharma Ltd. (Nasdaq: URGN) announced results from subgroup analyses of the pivotal ENVISION study, assessing the impact…
DaVita Inc. Q4 2024 Results DaVita Inc. (NYSE: DVA), a leading provider of dialysis services, has announced its financial and operational results for the fourth quarter and year ended December…
GE HealthCare Announces Q4 and Full Year 2024 Financial Results GE HealthCare (Nasdaq: GEHC) reported its financial results for the fourth quarter and full year ended December 31, 2024, showing…
Futibatinib Now Available in Italy for Cholangiocarcinoma Treatment, Announces Taiho Oncology Europe Taiho Oncology Europe GmbH has announced the availability of futibatinib in Italy for the treatment of cholangiocarcinoma (CCA),…